<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01179113</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00019850</org_study_id>
    <nct_id>NCT01179113</nct_id>
  </id_info>
  <brief_title>Esmolol Infusion During Laminectomy: Effect on Quality of Recovery</brief_title>
  <official_title>Esmolol Infusion for Maintaining Hemodynamic Stability During Single or Double Level Lumbar Laminectomy: Effect on Quality of Recovery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of esmolol, a drug which is commonly
      administered during surgery to help control blood pressure and heart rate, on postoperative
      pain levels and requirements for pain medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A common practice used to control autonomic responses during surgery is to administer
      beta-blockers intraoperatively. This practice has been shown to effectively blunt autonomic
      responses to intraoperative events. Several studies have shown that administration of
      beta-blockers can decrease intraoperative anesthetic requirements. Additionally, it has been
      demonstrated in several studies that intraoperative beta-blocker administration may actually
      decrease postoperative pain scores and opioid requirements, although these results are not
      entirely consistent. The mechanism by which the decrease in postoperative pain and narcotic
      requirements occurs is unclear. It has been postulated that esmolol may itself possess some
      analgesic-like properties, as was suggested by studies performed in rodent models. It has
      also been postulated that perioperative beta-blockade may attenuate the neuroendocrine stress
      response to surgery, thereby decreasing inflammatory responses in tissues; however, this
      theory was not supported by a study in which stress hormone levels were measured in patients
      who received beta-blockers and compared to a control group. Several studies which
      investigated the effects of beta-blockade on postoperative pain and opioid requirements
      compared the beta-blocker treatment group to an opioid treatment group, and did not include a
      true control group in which no treatment was given. Therefore, it is unclear whether the
      decrease in postoperative pain and opioid requirements in these studies was due to a true
      effect of the beta-blockers or whether it was due to an effect of the opioids.

      Therefore, the investigators propose a randomized, double-blinded, placebo-controlled study
      in which the investigators will compare an esmolol infusion treatment group to a normal
      saline infusion control group with regards to the effects on postoperative pain and opioid
      requirements. By setting up the study in this manner, the investigators will be able to
      clearly evaluate the effects of beta-blockers on postoperative pain scores and opioid
      requirements. The investigators chose to use esmolol both because it has a short half-life,
      so it is easy to titrate and administer as an infusion, and also because it is selective for
      beta-1 receptors, so deleterious effects of intraoperative hypotension should be minimized.
      The investigators chose to perform the study on patients who are undergoing single-level or
      double-level laminectomies because prior studies have investigated the effects of
      intraoperative beta-blockers on patients who are not chronic pain patients, and the
      investigators would like to research whether the results which have been suggested by prior
      studies are also applicable to patients who may have chronic pain, as this is the patients
      population that is most likely to experience high pain levels following surgery, and may
      benefit the most from reduction of postoperative pain levels.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The preliminary result didn't show any benefit.
  </why_stopped>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-operative Pain Using Verbal Rating Scale (VRS)</measure>
    <time_frame>1 day</time_frame>
    <description>Verbal Rating Scale goes from 0 to 10, where:
0 indicates= No pain&quot; and 10 indicates= The worst possible pain
The information was be recorded by study staff and data obtained from patient and patient charts from post-anesthesia care unit (PACU) stay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid Consumption in PACU Obtained From the Recorded Data</measure>
    <time_frame>1 day</time_frame>
    <description>Postoperative use of opioid (Hydromorphone) consumption inside hospital at PACU (recorded by study staff and data obtained from patient charts).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Nausea and Vomiting</measure>
    <time_frame>1 day</time_frame>
    <description>Number of participants that experienced Postoperative nausea and vomiting using at PACU</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Laminectomy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: Will receive a normal saline bolus during induction, and an infusion of normal saline intraoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esmolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive Esmolol Loading: 0.5 mg/kg bolus during induction Infusion: 15 mcg /kg/min, infusion intraoperatively</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol</intervention_name>
    <description>Esmolol group: Will receive 0.5 mg/kg IV bolus of esmolol during induction, and an infusion of esmolol at 0.3 mg/kg/hr intraoperatively.</description>
    <arm_group_label>Esmolol</arm_group_label>
    <other_name>Brevibloc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Loading: an equivalent volume for the Esmolol group Infusion: an equivalent volume for the Esmolol group</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled to undergo single-level or double-level laminectomy under general
             anesthesia

          -  Willingness and ability to sign an informed consent document

          -  No allergies to any of the anesthetic or analgesic medications being used for the
             study, as outlined in the study protocol

          -  Between 18-80 years of age

          -  American Society of Anesthesiologists (ASA) class I-III adults of either sex

        Exclusion Criteria:

          -  Patients who are ASA class IV or higher

          -  Patients with known allergy, hypersensitivity, or contraindication to the use of any
             of the medications being used for the study, as outlined in the study protocol

          -  Patients who are heavy chronic opioid users, defined for the purposes of this study as
             any patient who is taking the equivalent of 10mg of oral morphine per day or greater

          -  Pregnant or lactating women

          -  Patients with a history of drug or alcohol abuse within the past 3 months

          -  Patients with any other medical conditions or who are using any medications which may
             interfere with the conduct of the study (including patients taking clonidine, patients
             with EKG conduction defects and who are taking calcium channel blockers, patients with
             clinically significant congestive heart failure (CHF) or bronchospasm, or patients
             with second- or third-degree heart block, symptomatic sinus bradyarrhythmia, or
             nonsinus rhythm on preoperative EKG.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roya Yumul, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roya Yumul, MD., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2010</study_first_submitted>
  <study_first_submitted_qc>August 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2010</study_first_posted>
  <results_first_submitted>June 9, 2016</results_first_submitted>
  <results_first_submitted_qc>July 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 30, 2016</results_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Roya Yumul, M.D.,PhD.</investigator_full_name>
    <investigator_title>Residency program director, Department of anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Laminectomy</keyword>
  <keyword>Esmolol Infusion</keyword>
  <keyword>Quality of recovery</keyword>
  <keyword>beta-blockers</keyword>
  <keyword>Pain management</keyword>
  <keyword>Postoperative pain</keyword>
  <keyword>Opioid requirements</keyword>
  <keyword>Intraoperative esmolol infusion</keyword>
  <keyword>Return to normal activities of daily living</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esmolol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Prior to the day of surgery, potential study patients scheduled to undergo spine surgical procedures received a packet of materials from their surgeon. The packet contained an initial patient contact letter, a privacy information sheet, and the institution review board (IRB)-approved informed consent form.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>A normal saline bolus during induction, and an infusion of normal saline intraoperatively.</description>
        </group>
        <group group_id="P2">
          <title>Esmolol</title>
          <description>Loading: 0.5 mg/kg bolus during induction Infusion: 15 mcg /kg/min, infusion intraoperatively</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>A normal saline bolus during induction, and an infusion of normal saline intraoperatively.</description>
        </group>
        <group group_id="B2">
          <title>Esmolol</title>
          <description>Loading: 0.5 mg/kg bolus during induction Infusion: 15 mcg /kg/min, infusion intraoperatively</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="11"/>
                    <measurement group_id="B2" value="54" spread="16"/>
                    <measurement group_id="B3" value="57" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" spread="5"/>
                    <measurement group_id="B2" value="26" spread="4"/>
                    <measurement group_id="B3" value="26" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post-operative Pain Using Verbal Rating Scale (VRS)</title>
        <description>Verbal Rating Scale goes from 0 to 10, where:
0 indicates= No pain&quot; and 10 indicates= The worst possible pain
The information was be recorded by study staff and data obtained from patient and patient charts from post-anesthesia care unit (PACU) stay</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A normal saline bolus during induction, and an infusion of normal saline intraoperatively.</description>
          </group>
          <group group_id="O2">
            <title>Esmolol</title>
            <description>Loading: 0.5 mg/kg bolus during induction Infusion: 15 mcg /kg/min, infusion intraoperatively</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Pain Using Verbal Rating Scale (VRS)</title>
          <description>Verbal Rating Scale goes from 0 to 10, where:
0 indicates= No pain&quot; and 10 indicates= The worst possible pain
The information was be recorded by study staff and data obtained from patient and patient charts from post-anesthesia care unit (PACU) stay</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="4"/>
                    <measurement group_id="O2" value="5" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Consumption in PACU Obtained From the Recorded Data</title>
        <description>Postoperative use of opioid (Hydromorphone) consumption inside hospital at PACU (recorded by study staff and data obtained from patient charts).</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A normal saline bolus during induction, and an infusion of normal saline intraoperatively.</description>
          </group>
          <group group_id="O2">
            <title>Esmolol</title>
            <description>Loading: 0.5 mg/kg bolus during induction Infusion: 15 mcg /kg/min, infusion intraoperatively</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Consumption in PACU Obtained From the Recorded Data</title>
          <description>Postoperative use of opioid (Hydromorphone) consumption inside hospital at PACU (recorded by study staff and data obtained from patient charts).</description>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.6"/>
                    <measurement group_id="O2" value="2" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Nausea and Vomiting</title>
        <description>Number of participants that experienced Postoperative nausea and vomiting using at PACU</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A normal saline bolus during induction, and an infusion of normal saline intraoperatively.</description>
          </group>
          <group group_id="O2">
            <title>Esmolol</title>
            <description>Loading: 0.5 mg/kg bolus during induction Infusion: 15 mcg /kg/min, infusion intraoperatively</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Nausea and Vomiting</title>
          <description>Number of participants that experienced Postoperative nausea and vomiting using at PACU</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 day</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>A normal saline bolus during induction, and an infusion of normal saline intraoperatively.</description>
        </group>
        <group group_id="E2">
          <title>Esmolol</title>
          <description>Loading: 0.5 mg/kg bolus during induction Infusion: 15 mcg /kg/min, infusion intraoperatively</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Roya Yumu', Anesthesiology Program Director</name_or_title>
      <organization>Cedars Sinai Medical Center</organization>
      <phone>310-423-1682</phone>
      <email>Roya.Yumul@cshs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

